Novo Nordisk Launches New Insulin Injection Novopen Echo® In The US
Denmark-based pharmaceutical giant Novo Nordisk announced this week that it has launched insulin injection device NovoPen Echo® in the US. The new insulin injection pen is the first and currently the only pen device with half-unit dosing and memory function available in the country.
NovoPen Echo is the latest insulin delivery system from diabetes care company Novo Nordisk. It features half-unit dose increments for finer adjustments. It also features a memory function to record the dose and time passed since the last injection was administered.
Twelve removable skins including kid-friendly designs are available for NovoPen Echo.
Children with Diabetes founder Jeff Hitchcock said, "Children with type 1 diabetes have unique needs in regards to diabetes management… It is so important that new, innovative tools continue to be developed so that children and caregivers have options. NovoPen Echo, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home.”
NovoLog brand team Vice President George McAvoy said, “We are excited to make NovoPen Echo available in the United States for patients and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately.” An estimated 25.8 million people are affected by diabetes in the United States alone.
NovoPen Echo is available to patients with NovoLog PenFill cartridges. NovoLog (insulin aspart [rDNA origin] injection) is a synthetic insulin manufactured by Novo Nordisk to control high blood glucose levels in adults and children diagnosed with diabetes mellitus. NovoLog is a fast-acting insulin and not recommended for combined use with other insulin when used in either a pump or injections by syringe. Patients with very low blood sugar (hypoglycemia) are not advised to use NovoLog.
NovoPen Echo has already been launched in Europe, Canada, and Israel.